Neuropediatrics 1997; 28(1): 37-41
DOI: 10.1055/s-2007-973664
Original articles

© Hippokrates Verlag GmbH Stuttgart

Upregulation of Bcl-2 and Elevation of Ceramide in Batten Disease

K. Puranam1 , W.-H. Qian1 , K. Nikbakht1 , M. Venable2 , L. Obeid2 , Y. Hannun2 , R.-M. Boustany1
  • 1Departments of Pediatrics (Division of Pediatric Neurology) and Neurobiology (R.-M.B.) Duke University Medical Center, Durham, North Carolina, USA
  • 2Departments of Medicine, Divisions of Geriatrics (L.O. and M.V.) and Hematology-Oncology (Y.H.) and Cell Biology (Y.H. and L.O.) Duke University Medical Center, Durham, North Carolina, USA
Further Information

Publication History

Publication Date:
13 March 2007 (online)

Abstract

The late infantile and juvenile variants of Batten disease are genetically distinct neurodegenerative disorders. Hallmarks of Batten disease include cognitive and motor decline, seizures and blindness due to retinitis pigmentosa. Recently, the CLN3 gene responsible for the juvenile variant has been cloned. Also, apoptosis was proven to be the mechanism by which neurons and photoreceptors die. This paper provides mechanistic support for the occurrence of apoptosis in this disease: There was marked upregulation of Bcl-2 in brain from the late infantile and juvenile types at the protein and RNA levels both by immunocytochemistry and by Northern blot analysis; there were also a 42 % to 197 % increase in brain ceramide determinations in brains from three patients with the juvenile type and three patients with the late infantile type. Double immunolabeling of brain sections for apoptosis and Bcl-2 supported a protective role for Bcl-2 in the juvenile form of Batten disease. These results raise the possibility that the intact CLN3 gene is normally antiapoptotic, and that it could be an upstream regulator of ceramide.

    >